Trump launch of cheaper weight-loss drugs cut short after health executive collapses in Oval Office: Live updates

Robert F. Kennedy Jr., the secretary of Health and Human Services, was seen walking away from the man who collapsed during a White House press conference, sparking some criticism on social media.

Clarifying the incident, White House Deputy Press Secretary Kush Desai wrote on X, “The Secretary rushed to get medical assistance while others tended to the man.”

When asked about potential risks associated with weight-loss drugs, President Donald Trump said, “I’ve heard about very little side effects with respect to these drugs.”

“It’s all positive,” he added. “That’s usually not the case.”

Dr. Mehmet Oz, the head of the Centers for Medicare & Medicaid Services, said that ordinary Americans will now be able to access weight-loss medications.

“We are democratizing access to these medications,” he said during a White House press conference on Thursday. “The forgotten man will be able to afford these drugs now.”

The Trump administration has reached a deal with two drug makers to lower prices of popular GLP-1 diabetes medications for Americans on Medicare and Medicaid as well as for those who purchase the drugs on the administration’s forthcoming TrumpRx web site.

Read more from White House Correspondent Andrew Feinberg:

The Oval Office press conference on weight-loss medications will “resume shortly,” White House Press Secretary Karoline Leavitt announced after a businessman collapsed while standing behind President Trump.

The man is believed to be Novo Nordisk executive Gordon Findlay.

Dr. Mehmet Oz, the Administrator for the Centers for Medicare & Medicaid Services, said during the GLP-1 press conference Thursday that he was hoping the reduction in fertility drugs would lose to “lots of Trump babies.”

“We’ve dropped the infertility drugs to make lots of Trump babies I’m hoping by the midterms,” Dr. Oz said.

Camera feed to the White House’s GLP-1 event was cut short after an event attendee passed out on the ground.

Kennedy asserted that the Trump administration’s deal with drugmakers to make GLP-1s more affordable will allow Americans to lose “125 million pounds” by this time next year.

Health and Human Services Secretary Robert F. Kennedy Jr. praised President Donald Trump for making GLP-1s such as Zepbound and Wegovy more affordable to people.

“Obesity is a disease of poverty. Overwhelming and these drug have only been available for people who have wealth,” Kennedy said.